Disruption has hit pharma – are you ready?
Jonas Pedersèn, CEO
Strategic intelligence for a fiercely competitive marketplace
In the pharmaceutical industry, change has long been known as the only constant. But the last few years have seen the industry challenged and reshaped by drastic internal disruption and external paradigm shifts. The increasing adoption of health economics and outcomes research (HEOR) into payer decision-making means that efficacy and safety alone are no longer enough to launch even the most straightforward small-molecule drug directly to profit. The rise of biologicals, biomarker-targeted drugs, gene-specific medications, and immune checkpoint inhibitors have provided breakthrough therapies potentially benefitting millions. At the same time, insurance to cover these drugs is chaotic in some countries, rigidly stratified by government fiat in some, and nonexistent in others.
Despite this challenging environment, the pharma industry continues to grow. Global revenue grew by 41% from 2003-2015,1 and the prescription drug market is projected to grow at a compound annual rate of 6.5% from 2016 to 2022, reaching £760 billion.2 With drug development becoming ever more expensive, the pressure is on even the most established companies to have winners in their pipelines. Meanwhile, start-ups working at the forefront of medical research may find themselves seeing enormous infusions of cash from established companies, only to have later developments dampen enthusiasm. But when it all comes together – when the drug does what it’s meant to do, and the patient improves and is not bankrupted by the cost burden – the rewards for the pharma company, for the patient, and for society in general are potentially greater than ever before. Because of this, the number of stakeholders is growing, specialization is proliferating, and it is becoming increasingly difficult for anyone to have a true holistic understanding of the market in its entirety.
These market transformations have necessitated changes in the nature and purpose of strategic intelligence (SI). Data, once a challenge to find, now floods us constantly, overwhelming our vision of the market with endless opportunities to second-guess ourselves and focus on the wrong things. In this dynamic environment, it is not enough to merely know what the competition is doing, but also what they’re not doing and why they’re not doing it. It is also vital to consider how your competition views you by taking an honest look at your organization’s strengths and challenges. SI sees through the data clutter and false signals in order to fully grasp the ramifications of all these elements shifting in and out of play. By keeping firmly grounded in an understanding of the competition and larger market trends affecting each individual market niche, SI offers pharma companies a strategic vision of the choices competitors have to make, and the options before them, both currently and in the future.
A drug in a pipeline is on a fixed course. Drug pipeline timelines may be shortened by various means, but the course of the drug through the approval process does not allow for quick responses to new competitive realities. Thus, anything less than full understanding of the multiplicity of variables affecting competitors represents a blind spot that may grow in size and financial risk with every step toward marketability.
This paper looks at key changes in the pharma landscape through the lens of strategic intelligence, and considers how this powerful tool can help pharma stakeholders grasp the full picture of the competitive environment they intend to enter.
Jonas Pedersèn, Non-Executive Director
Jonas is a Non-Executive Director and co-founder of Deallus. Previously, Jonas was the Head and Director of Competitive Intelligence at Amgen Inc., and prior to this role he worked for Therapy Area Pain Control within AstraZeneca R&D. Before joining the life science sector, Jonas was an Assistant Professor and acting Deputy Director at the Department of Musculoskeletal Research at The National Institute for Working Life in Sweden. Over his career, Jonas has facilitated over 120 strategic workshops such as war games and scenario analysis events and is experienced in all facets of the strategy consulting mix. More about Jonas
As COVID-19 continues to disrupt normalcy across the globe, China is responding with innovation in online health delivery and telemedicine. How has China encouraged telemedicine uptake? What are the factors contributing to China’s relatively quick utilization of telemedicine in the face of COVID-19? And what learnings can we gain from taking a closer look? We explore these questions in our latest addition to our COVID-19+Pharma Series.
COVID-19 is throwing a wrench in years’ worth of launch planning, introducing complications and delays into the regulatory process and severely constricting promotional and educational opportunities for new products. How is the pharmaceutical industry responding to these changes in well-laid plans? How are regulatory bodies responding? We consider the potential impact of the pandemic on launch timing and strategy here.
As the impact of COVID-19 pandemic continues to expand globally, pharmaceutical and biotech players are beginning to feel the disruptive effects of the outbreak. New clinical trials will be significantly delayed as companies continue to face challenges arising from COVID-19, from potential patient quarantines, to site closures, travel limitations or interruptions to the supply chain for new investigational products.
Deallus is excited to announce that Jenny Cummins will be partnering with Deallus as a Strategic Advisor. Jenny’s experience in formulating strategic direction within and outside of pharmaceutical companies is something we are excited to add to our panel of strategic advisors. Our clients will benefit from her expertise in the healthcare sector as well as her impressive leadership, communication, and facilitation skills.